| DEFINIUM THERAPEUTICS |
| Kanada |
| Gesundheit |
| CA24477V1058 / A420P3 |
| MMQ0 (Frankfurt) / DFTX (NASDAQ) |
| FRA:MMQ0, ETR:MMQ0, MMQ0:GR, NASDAQ:DFTX |
| - |
| https://definiumtx.com/ |
|
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT1..
>Volltext.. |
| 4551.22 Mio. EUR |
| 3631.79 Mio. EUR |
| - |
| -200.66 Mio. EUR |
| -311.98 Mio. EUR |
| -3.03 EUR |
| 32.16 Mio. EUR |
| 577.84 Mio. EUR |
| -147.04 Mio. EUR |
| 6.89 |
| - |
| -218.66% |
| - |
| - |
| - |
| 5 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.666.052 Euro. |
| DEFINIUM |
| 30.09.26 |
|